BCRX

Biocryst Pharmaceuticals Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↑ 9/10
  • Value↑ 8/10
Biocryst Pharmaceuticals sales and earnings growth
BCRX Growth
Great
  • Revenue Y/Y↑ 94.10%
  • EPS Y/Y↑ 393.02%
  • FCF Y/Y↑ 748.99%
Biocryst Pharmaceuticals gross and profit margin trends
BCRX Profitability
Great
  • Gross margin ↑ 97.80%
  • EPS margin↑ 30.20%
  • ROIC 5Y↑ -0.53%
Biocryst Pharmaceuticals net debt vs free cash flow
BCRX Risk
Poor
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 1.1
  • Interest coverage↓ 4.4

Biocryst Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.

More Biotechnology stocks ↗